²©²ÊÓÎÏ·

²©²ÊÓÎÏ·., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership.

²©²ÊÓÎÏ· announced a strategic collaboration with Galapagos NV to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications.

²©²ÊÓÎÏ· and Novo Holdings today announced that Novo Holdings has completed its previously announced acquisition of ²©²ÊÓÎÏ· in an all-cash transaction with a total enterprise value of approximately $16.5 billion.

²©²ÊÓÎÏ· and Novo Holdings today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days.

²©²ÊÓÎÏ· and Novo Holdings today announced that the European Commission has granted unconditional approval for the pending transaction under which Novo Holdings will acquire ²©²ÊÓÎÏ·.

The MSA encompasses development of ISM-001 from cell line development through to finished clinical trial product supply; work will be performed in the USA and the EU.

²©²ÊÓÎÏ·, the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers:

²©²ÊÓÎÏ· announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden.

²©²ÊÓÎÏ· today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany.